We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+6.22%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$212M
AUM Growth
+$16.7M
(+8.5%)
Cap. Flow
+$11.9M
Cap. Flow
% of AUM
5.62%
Top 10 Holdings %
Top 10 Hldgs %
46.87%
Holding
65
New
3
Increased
31
Reduced
4
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LHCG
LHC Group LLC
LHCG
|
+$4.64M |
| 2 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$4.57M |
| 3 |
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
|
+$4.24M |
| 4 |
ESPR
Esperion Therapeutics
ESPR
|
+$1.95M |
| 5 |
AtriCure
ATRC
|
+$1.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVDQ
Novadaq Technologies Inc.
NVDQ
|
+$3.97M |
| 2 |
Ligand Pharmaceuticals
LGND
|
+$3.7M |
| 3 |
LCI
Lannett Company, Inc.
LCI
|
+$3.37M |
| 4 |
STAAR Surgical
STAA
|
+$2.53M |
| 5 |
NeoGenomics
NEO
|
+$1.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.38% |
| 2 | Energy | 2.37% |
| 3 | Consumer Staples | 0.82% |
| 4 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alkermes
ALKS
$8.22B
| $3.51M | 1.65% |
54,533
+4,936
| +10% | +$302K |
|
|
CPHD
27
DELISTED
Cepheid Inc
CPHD
| $3.34M | 1.57% |
54,691
+4,907
| +10% | +$280K |
|
28
HealthStream
HSTM
$819M
| $3.06M | 1.44% |
100,754
+9,064
| +10% | +$260K |
|
|
STRM
29
DELISTED
Streamline Health Solutions
STRM
| $3.04M | 1.43% |
72,495
+6,079
| +9% | +$230K |
|
30
Vertex Pharmaceuticals
VRTX
$121B
| $2.6M | 1.23% |
21,098
+1,733
| +9% | +$218K |
|
31
Standard BioTools
LAB
$340M
| $2.38M | 1.12% |
98,209
+8,717
| +10% | +$275K |
|
32
BioMarin Pharmaceuticals
BMRN
$11.6B
| $2.24M | 1.05% |
16,365
-8,241
| -33% | -$1.02M |
|
|
BLUE
33
DELISTED
bluebird bio
BLUE
| $1.96M | 0.92% |
896
-472
| -35% | -$962K |
|
|
STKL
34
DELISTED
SunOpta
STKL
| $1.74M | 0.82% |
161,690
+14,272
| +10% | +$151K |
|
35
Verastem
VSTM
$510M
| $1.72M | 0.81% |
19,045
+1,718
| +10% | +$182K |
|
|
ESPR
36
DELISTED
Esperion Therapeutics
ESPR
| $1.63M | 0.77% |
+19,930
| New | +$1.95M |
|
37
Cytokinetics
CYTK
$10.5B
| $1.47M | 0.69% |
218,792
+19,778
| +10% | +$130K |
|
|
PETX
38
DELISTED
Aratana Therapeutics, Inc.
PETX
| $1.07M | 0.5% |
70,620
+6,414
| +10% | +$92.6K |
|
39
Humana
HUM
$43.7B
| $677K | 0.32% |
3,540
| – | – |
|
40
Elevance Health
ELV
$81.5B
| $672K | 0.32% |
4,095
| – | – |
|
|
AET
41
DELISTED
Aetna Inc
AET
| $665K | 0.31% |
5,215
| – | – |
|
42
United Therapeutics
UTHR
$25.8B
| $664K | 0.31% |
3,820
| – | – |
|
43
Viatris
VTRS
$20.4B
| $663K | 0.31% |
9,775
| – | – |
|
|
ENDP
44
DELISTED
Endo International plc
ENDP
| $650K | 0.31% |
8,161
| – | – |
|
|
AGN
45
DELISTED
Allergan plc
AGN
| $618K | 0.29% |
2,035
| – | – |
|
46
Novartis
NVS
$297B
| $597K | 0.28% |
6,774
| – | – |
|
47
Bristol-Myers Squibb
BMY
$133B
| $552K | 0.26% |
8,290
| – | – |
|
|
CELG
48
DELISTED
Celgene Corp
CELG
| $495K | 0.23% |
4,280
| – | – |
|
49
Becton Dickinson
BDX
$45.6B
| $481K | 0.23% |
3,480
| – | – |
|
50
Eli Lilly
LLY
$1.02T
| $459K | 0.22% |
5,495
| – | – |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q2 2015 Portfolio in Review
As of Q2 2015, First Light Asset Management held 65 positions worth $212M, up 8.5% from $196M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
First Light Asset Management deployed $11.9M of net new capital in Q2 2015, opening 3 new positions and adding to 31 existing holdings. Its largest new stake was LHC Group LLC: 131,467 shares worth $5.03M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 89% a quarter earlier, followed by Energy and Consumer Staples.
On the sell side, the largest reduction was Ligand Pharmaceuticals, an estimated $3.7M trimmed.
- First Light Asset Management's largest Q2 2015 buy was LHC Group LLC: 131,467 shares worth $5.03M.
- First Light Asset Management added most to AMAG Pharmaceuticals in Q2 2015, an estimated $4.57M increase.
- First Light Asset Management's biggest Q2 2015 reduction was Ligand Pharmaceuticals, cutting an estimated $3.7M.
- First Light Asset Management fully exited Novadaq Technologies Inc. in Q2 2015, selling an estimated $3.97M.
- First Light Asset Management's ten largest holdings make up 47% of its $212M portfolio in Q2 2015.
- First Light Asset Management opened 3 new positions and closed 4 in Q2 2015.
- First Light Asset Management's portfolio value rose 8.5% quarter-over-quarter to $212M.
Based on First Light Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.